Role of PPARα and its agonist in renal diseases

Heng Lin, Ching Feng Cheng, Hsi Hsien Chen

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Peroxisome proliferator-activated receptor (PPAR)-α, a member of a large nuclear receptor superfamily, plays a major role in the regulation of lipid metabolism. Recently, PPARα activation has been shown to confer additional benefits on endothelial function, kidney function, and anti-inflammation, suggesting that PPARα agonists may be good candidates for treating acute renal failure. In clinical application, PPAR-α activators, such as hypolipidemic drugs in fibric acid class, were proven to have therapeutic effects on metabolic syndrome and cardiovascular disease. This paper focuses on signaling pathways, ligand selectivity, and physio-pathological roles of PPARα in kidney diseases and the therapeutic utility of PPARα modulators in the treatment of diabetes and inflammation-induced nephropathy. Implication of new and more potent PPAR-α activators could provide important insights into the overall benefits of activating PPAR-α clinically for the treatment of dyslipidemia and the prevention of diabetic or inflammation-induced nephropathy in the future.

Original languageEnglish
Article number345098
JournalPPAR Research
DOIs
Publication statusPublished - 2010

Fingerprint

Peroxisome Proliferator-Activated Receptors
Kidney
Inflammation
Hypolipidemic Agents
Metabolic Diseases
Kidney Diseases
Therapeutic Uses
Cytoplasmic and Nuclear Receptors
Dyslipidemias
Lipid Metabolism
Acute Kidney Injury
Cardiovascular Diseases
Therapeutics
Ligands

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Drug Discovery

Cite this

Role of PPARα and its agonist in renal diseases. / Lin, Heng; Cheng, Ching Feng; Chen, Hsi Hsien.

In: PPAR Research, 2010.

Research output: Contribution to journalArticle

@article{c421cb3fdf534a908672cdf170a78154,
title = "Role of PPARα and its agonist in renal diseases",
abstract = "Peroxisome proliferator-activated receptor (PPAR)-α, a member of a large nuclear receptor superfamily, plays a major role in the regulation of lipid metabolism. Recently, PPARα activation has been shown to confer additional benefits on endothelial function, kidney function, and anti-inflammation, suggesting that PPARα agonists may be good candidates for treating acute renal failure. In clinical application, PPAR-α activators, such as hypolipidemic drugs in fibric acid class, were proven to have therapeutic effects on metabolic syndrome and cardiovascular disease. This paper focuses on signaling pathways, ligand selectivity, and physio-pathological roles of PPARα in kidney diseases and the therapeutic utility of PPARα modulators in the treatment of diabetes and inflammation-induced nephropathy. Implication of new and more potent PPAR-α activators could provide important insights into the overall benefits of activating PPAR-α clinically for the treatment of dyslipidemia and the prevention of diabetic or inflammation-induced nephropathy in the future.",
author = "Heng Lin and Cheng, {Ching Feng} and Chen, {Hsi Hsien}",
year = "2010",
doi = "10.1155/2010/345098",
language = "English",
journal = "PPAR Research",
issn = "1687-4757",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Role of PPARα and its agonist in renal diseases

AU - Lin, Heng

AU - Cheng, Ching Feng

AU - Chen, Hsi Hsien

PY - 2010

Y1 - 2010

N2 - Peroxisome proliferator-activated receptor (PPAR)-α, a member of a large nuclear receptor superfamily, plays a major role in the regulation of lipid metabolism. Recently, PPARα activation has been shown to confer additional benefits on endothelial function, kidney function, and anti-inflammation, suggesting that PPARα agonists may be good candidates for treating acute renal failure. In clinical application, PPAR-α activators, such as hypolipidemic drugs in fibric acid class, were proven to have therapeutic effects on metabolic syndrome and cardiovascular disease. This paper focuses on signaling pathways, ligand selectivity, and physio-pathological roles of PPARα in kidney diseases and the therapeutic utility of PPARα modulators in the treatment of diabetes and inflammation-induced nephropathy. Implication of new and more potent PPAR-α activators could provide important insights into the overall benefits of activating PPAR-α clinically for the treatment of dyslipidemia and the prevention of diabetic or inflammation-induced nephropathy in the future.

AB - Peroxisome proliferator-activated receptor (PPAR)-α, a member of a large nuclear receptor superfamily, plays a major role in the regulation of lipid metabolism. Recently, PPARα activation has been shown to confer additional benefits on endothelial function, kidney function, and anti-inflammation, suggesting that PPARα agonists may be good candidates for treating acute renal failure. In clinical application, PPAR-α activators, such as hypolipidemic drugs in fibric acid class, were proven to have therapeutic effects on metabolic syndrome and cardiovascular disease. This paper focuses on signaling pathways, ligand selectivity, and physio-pathological roles of PPARα in kidney diseases and the therapeutic utility of PPARα modulators in the treatment of diabetes and inflammation-induced nephropathy. Implication of new and more potent PPAR-α activators could provide important insights into the overall benefits of activating PPAR-α clinically for the treatment of dyslipidemia and the prevention of diabetic or inflammation-induced nephropathy in the future.

UR - http://www.scopus.com/inward/record.url?scp=78650796942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650796942&partnerID=8YFLogxK

U2 - 10.1155/2010/345098

DO - 10.1155/2010/345098

M3 - Article

C2 - 21076544

AN - SCOPUS:78650796942

JO - PPAR Research

JF - PPAR Research

SN - 1687-4757

M1 - 345098

ER -